Gilead Sciences Inc. (GILD) announced interim data from the Phase 2 ELECTRON study of once-daily oral agent GS-7977 plus ribavirin Thursday morning, in treatment-naïve patients with genotype 1 chronic hepatitis C virus infection. Of the 25 patients who completed 12 weeks of treatment with the GS-7977-based regimen, 88 percent of patients remained HCV RNA undetectable four weeks after completion of treatment.
Gilead Sciences gapped open sharply higher Thursday, but retreated during the first half of the morning, before settling into a range. The stock closed up by 5.64 at $52.25 on above average volume. Gilead broke out to a 2-month high and re-crossed its 50-day moving average.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.